← Eichor
Condition: Metastatic Colorectal Cancer Mcrc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Colorectal Cancer Mcrc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic
Phase 1 · 26 location(s) · R-Pharm · NCT07543744FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-S
Phase 2 · 13 location(s) · Oncolytics Biotech · NCT07446322A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastati
Phase 1/Phase 2 · 1 location(s) · CuraCell TX AB · NCT07255664Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Phase N/A · 13 location(s) · Swiss Cancer Institute · NCT07617610Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Phase 2 · 1 location(s) · Fudan University · NCT05229003XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer
NA · 1 location(s) · Oncosyne AS · NCT07171554Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
Phase 1/Phase 2 · 1 location(s) · HonorHealth Research Institute · NCT07463599Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorec
Phase N/A · 1 location(s) · Niguarda Hospital · NCT07536113Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06825624ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
Phase 2 · 1 location(s) · Beijing Hospital · NCT06321081Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224724A Clinical Study of Arfolitixorin in Patients With mCRC
Phase 1/Phase 2 · 3 location(s) · Isofol Medical AB · NCT06922383Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
Phase 2 · 1 location(s) · First Affiliated Hospital of Wenzhou Medical University · NCT06485713A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Phase N/A · 1 location(s) · Fudan University · NCT06749015Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
Phase N/A · 7 location(s) · Arbeitsgemeinschaft medikamentoese Tumortherapie · NCT06678919Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Phase 2 · 2 location(s) · Ruijin Hospital · NCT07085169Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients
Phase 1/Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06202001LYL273 for Patients With Relapsed or Refractory mCRC
Phase 1/Phase 2 · 4 location(s) · Lyell Immunopharma, Inc. · NCT05319314Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Pa
Phase 2 · 1 location(s) · Sergey Orlov, MD · NCT06949982Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
Phase 2 · 9 location(s) · GERCOR - Multidisciplinary Oncology Cooperative Group · NCT05310643Streamlining Radioembolization for CCC and Metastatic Liver Cancer
Phase N/A · 4 location(s) · Seoul National University Hospital · NCT07043387PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Color
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05286814Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07724223TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Phase 2 · 3 location(s) · Teclison Ltd. · NCT04701476A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITF
Phase 2 · 14 location(s) · SCRI Development Innovations, LLC · NCT07011576Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-80
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06149481A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combinat
Phase 2/Phase 3 · 281 location(s) · Bristol-Myers Squibb · NCT07221357
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.